BREAST CANCER

A review of results from the EMERALD trial investigating elacestrant in patients with ESR1-mutated metastatic breast cancer.

Rebecca A. Shatsky, MD, reviews biomarker testing guideline recommendations for patients with breast cancer and discusses testing practices upon progression.

An expert on breast cancer provides clinical insights on liquid and tissue biopsies for patients with metastatic disease.

A medical oncologist discusses molecular biomarkers identified in patients with metastatic breast cancer and compares ESR1 with other genetic mutations.

Rebecca A. Shatsky, MD, provides an overview of ER+/HER2- metastatic breast cancer and discusses its incidence and prevalence.

During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, and participants discussed switching CDK4/6 inhibitors and continuing use beyond progression in patients with metastatic breast cancer. This is the first of 2 articles based on this event.

IDE161 now has 2 fast track designations from the FDA for patients with breast cancer and ovarian cancer. The agent continues to be evaluated in a first-in-human, phase 1 study for patients with advanced solid tumors.

Results from a new study could lead to the development of biomarkers for predicting treatment response and the implementation of strategies to address acquired resistance of CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Tiffany A. Traina, MD, reviewed data from the TROPiCS-02 and DESTINY-Breast04 and discussed using antibody-drug conjugates in patients with metastatic breast cancer.

In the second article of a 2-part series, Aditya Bardia, MD, MPH, leads a discussion on the practice-changing use of sacituzumab govitecan and trastuzumab deruxtecan for patients with advanced breast cancer.

Fertility preservation should be offered to anyone who is interested in becoming pregnant after chemotherapy for breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Aditya Bardia, MD, MPH, discussed treatment approaches for a patient with hormone receptor–positive, HER2- negative metastatic breast cancer?

In the second article of a 2-part series, Joyce O’Shaughnessy, MD, discusses the most recent findings from the phase 3 EMERALD study for patients with hormone receptor–positive metastatic breast cancer.

In the first article of a 2-part series, Aditya Bardia, MD, MPH, leads a discussion on what factors influence sequencing treatment for patients with estrogen receptor positive advanced breast cancer.

A number of trials evaluating rintatolimod as a combinational therapy for a wide range of solid tumor types are underway and planned, including in pancreatic and breast cancer.

According to Erica Mayer, MD, MPH, an analysis of the PALLAS study that patients with a higher BMI appeared to have less toxicity from the CDK4/6 inhibitor, palbociclib, and fewer cases of early discontinuation due to toxicity.

An era of advanced molecular testing and personalized medicine has allowed for the de-escalation of breast cancer treatment for many patients. This is part 1 of a 2-part series on overtreatment of breast cancer.

Before closing out their module on ESR1 mutation, panelists identify its impact on treatment options for patients diagnosed with HR+/HER2- metastatic breast cancer.

In the context of ESR1 mutation in HR+/HER2- metastatic breast cancer, key opinion leaders consider ideal testing modalities and timing to improve patient outcomes.

Andreas Varkaris, MD, PhD, discusses PIK3CA mutations in breast cancer and the novel therapies being developed to treat these tumors.

Nicholas J. Robert, MD, discusses a study of the social determinants of a patient’s health related to the use of genomic testing in women with breast cancer.

In this first part of a 2-article series, Joyce O’Shaughnessy, MD, recent updates to treatment and testing guidelines for patients with advanced breast cancer whose disease harbors an ESR1 mutation.

Docetaxel with carboplatin, trastuzumab, and pertuzumab has led to improved overall survival in patients with HER2-positive metastatic breast cancer. These findings led to the evaluation of dual blockade therapy in the neoadjuvant and adjuvant settings.

Centering discussion on the first patient case, panelists reflect on the importance of ESR1 mutation in the setting of HR+/HER2- metastatic breast cancer.

Focused discussion on the evolving role of germline testing in HR+/HER2- metastatic breast cancer and how it may impact treatment pathways.